Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaumont-Gistoux – page 67

1 874 clinical trials in Chaumont-Gistoux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaumont-Gistoux at a glance
1 874
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 874 trials in Chaumont-Gistoux

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Sarcopenia

Not yet recruiting

Evaluation of BIO-101 versus placebo for treating severe sarcopenia in elderly patients with reduced mobility

Investigational
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:20-HYDROXYECDYSONE
  • Sponsor:Biophytis

Transitional cell carcinoma

Not yet recruiting

Study of disitamab vedotin alone or with pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Cardiac failure+5

Not yet recruiting

Study of cardiac atrial stem cells injected into heart muscle for treating advanced heart failure in patients with prior heart attack and reduced heart function

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Odyssey Therapeutics Inc.

Gastrointestinal disorder

Not yet recruiting

Study on the Safety and Effects of Orziloben (NST-6179) for Patients with Intestinal Failure-Associated Liver Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Orziloben
  • Sponsor:NorthSea Therapeutics B.V.

Loss of consciousness

Not yet recruiting

Study on Zolpidem's Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mannitol
  • Sponsor:Universite De Liege

COVID-19

Not yet recruiting

Study on COVID-19 Immunity in Immunocompromised Adults Using Raxtozinameran and Bretovameran in Belgium

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Sciensano

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaumont-Gistoux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI De-prescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The study explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment protocols for long-term digestive health management.

02 Digestive Health Studies

Research examining the effectiveness of different management strategies for heartburn and reflux symptoms. The trials evaluate various therapeutic approaches, including alginate formulations as alternative treatments.

  • Symptom Management
  • Treatment Optimization
  • Patient-Centered Care

These investigations aim to improve quality of life for patients while identifying more targeted and efficient treatment strategies.

03 Primary Care Innovation

Forward-thinking research in primary care settings focusing on medication optimization and patient-centered approaches to chronic condition management.

  • Medication Management
  • Evidence-Based Protocols
  • Clinical Practice Enhancement

This research aims to establish better guidelines for long-term medication management in primary care practices.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.